Empagliflozin for treating chronic kidney disease (TA942)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Targeted-release budesonide for treating primary IgA nephropathy (TA937)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Difelikefalin for treating pruritus in people having haemodialysis (TA890)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 May 2023
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 May 2023
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2023
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 September 2022
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 July 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Dapagliflozin for treating chronic kidney disease (TA775)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 January 2022Published: 4 September 2019
Chronic kidney disease: assessment and management (NG203)Product type:GuidanceProgramme:NICE guidelineLast updated: 24 November 2021Published: 25 August 2021
Laparoscopic renal denervation for loin pain haematuria syndrome (IPG709)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 October 2021
Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access (IPG710)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 October 2021
Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 5 August 2020
Patiromer for treating hyperkalaemia (TA623)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 February 2020
Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)Product type:GuidanceProgramme:Diagnostics guidancePublished: 13 November 2019
Renal replacement therapy and conservative management (NG107)Product type:GuidanceProgramme:NICE guidelinePublished: 3 October 2018
Robot-assisted kidney transplant (IPG609)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 April 2018
Immunosuppressive therapy for kidney transplant in adults (TA481)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Immunosuppressive therapy for kidney transplant in children and young people (TA482)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)Product type:GuidanceProgramme:Diagnostics guidancePublished: 21 June 2017
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2015
Single-port laparoscopic nephrectomy (IPG414)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 November 2011
Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 January 2009
Laparoscopic deroofing of simple renal cysts (IPG226)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 July 2007
Laparoscopic insertion of peritoneal dialysis catheter (IPG208)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 February 2007
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2007
Laparoscopic nephrectomy (including nephroureterectomy) (IPG136)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 August 2005
Laparoscopic live donor simple nephrectomy (IPG57)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 May 2004
PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)Product type:AdviceProgramme:Medtech innovation briefingPublished: 13 December 2022
Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 August 2020
The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)Product type:AdviceProgramme:Medtech innovation briefingPublished: 19 November 2014
Renal replacement therapy services for adults (QS72)Product type:Quality standardLast updated: 3 October 2018Published: 28 November 2014
Chronic kidney disease in adults (QS5)Product type:Quality standardLast updated: 27 July 2017Published: 30 March 2011
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 8 January 2025
Sparsentan for treating primary IgA nephropathy [ID6308]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 30 April 2025
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 August 2025
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over TS ID 10761Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome TS ID 9998Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Iptacopan for treating complement 3 glomerulopathy ID6283Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Obinutuzumab for treating lupus nephritis ID 6420Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Healthy.io test for home testing of urine albumin to creatinine ratioStatus:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Dapagliflozin for treating chronic kidney disease [ID6411]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC